We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
-6.71%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.79B
AUM Growth
-$16.3M
Cap. Flow
+$777M
Cap. Flow %
13.41%
Top 10 Hldgs %
69.76%
Holding
51
New
7
Increased
15
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$308M
2
XLRN
Acceleron Pharma
XLRN
+$187M
3
FOLD
Amicus Therapeutics
FOLD
+$50.3M
4
DSGN icon
Design Therapeutics
DSGN
+$49.5M
5
APLS
Apellis Pharmaceuticals
APLS
+$47.3M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$300M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$18.9M
3
ITOS
iTeos Therapeutics
ITOS
+$15.6M
4
TVTX icon
Travere Therapeutics
TVTX
+$15.2M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 93.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$828M 14.31%
9,000,000
– –
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$801M 13.83%
4,675,000
+140,000
+3% +$27.7M
UTHR icon
3
United Therapeutics
UTHR
$25.9B
$502M 8.67%
3,000,000
+150,000
+5% +$25M
XLRN
4
DELISTED
Acceleron Pharma
XLRN
$407M 7.03%
3,000,000
+1,450,000
+94% +$187M
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$124B
$301M 5.2%
+1,400,000
New +$308M
ARNA
6
DELISTED
Arena Pharmaceuticals Inc
ARNA
$281M 4.85%
4,050,000
-140,000
-3% -$10.8M
ARGX icon
7
argenx
ARGX
$54.9B
$255M 4.4%
925,500
+23,000
+3% +$7.27M
IOVA icon
8
Iovance Biotherapeutics
IOVA
$2.03B
$253M 4.37%
8,000,000
+500,000
+7% +$20.7M
MDGL icon
9
Madrigal Pharmaceuticals
MDGL
$12.4B
$167M 2.88%
1,425,000
+200,000
+16% +$23.3M
SRPT icon
10
Sarepta Therapeutics
SRPT
$1.64B
$160M 2.77%
2,150,000
+400,000
+23% +$36.9M
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$11.9B
$125M 2.15%
1,650,000
– –
FOLD
12
DELISTED
Amicus Therapeutics
FOLD
$121M 2.09%
12,250,000
+3,250,000
+36% +$50.3M
KURA icon
13
Kura Oncology
KURA
$785M
$113M 1.95%
4,000,000
– –
MRSN
14
DELISTED
Mersana Therapeutics
MRSN
$110M 1.9%
272,000
– –
ADVM
15
DELISTED
Adverum Biotechnologies
ADVM
$78.9M 1.36%
800,000
– –
PMVP icon
16
PMV Pharmaceuticals
PMVP
$57.6M
$77.6M 1.34%
2,360,267
+10,000
+0.4% +$394K
CNST
17
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$69M 1.19%
2,950,000
– –
XENE icon
18
Xenon Pharmaceuticals
XENE
$6.15B
$65.3M 1.13%
3,650,000
+850,000
+30% +$14.4M
ACAD icon
19
Acadia Pharmaceuticals
ACAD
$4.45B
$64.5M 1.11%
2,500,000
+550,000
+28% +$24.2M
TRIL
20
DELISTED
Trillium Therapeutics Inc.
TRIL
$61.2M 1.06%
5,700,000
-100,000
-2% -$1.24M
SNDX icon
21
Syndax Pharmaceuticals
SNDX
$1.68B
$55.9M 0.97%
2,500,000
+2,050,000
+456% +$46.3M
RLMD icon
22
Relmada Therapeutics
RLMD
$539M
$53.7M 0.93%
1,525,000
– –
MRNS
23
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$50.1M 0.86%
3,235,000
+2,858
+0.1% +$41.3K
PRAX icon
24
Praxis Precision Medicines
PRAX
$8.14B
$47.4M 0.82%
106,433
+3,400
+3% +$2.42M
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
$46.8M 0.81%
10,300,000
– –
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, Avoro Capital Advisors held 51 positions worth $5.79B, down 0.28% from $5.81B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Avoro Capital Advisors deployed $777M of net new capital in Q1 2021, opening 7 new positions and adding to 15 existing holdings. Its largest new stake was Vertex Pharmaceuticals: 1,400,000 shares worth $301M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was Deciphera Pharmaceuticals, Inc. Common Stock, an estimated $18.9M trimmed.

  • Avoro Capital Advisors's largest Q1 2021 buy was Vertex Pharmaceuticals: 1,400,000 shares worth $301M.
  • Avoro Capital Advisors added most to Acceleron Pharma in Q1 2021, an estimated $187M increase.
  • Avoro Capital Advisors's biggest Q1 2021 reduction was Deciphera Pharmaceuticals, Inc. Common Stock, cutting an estimated $18.9M.
  • Avoro Capital Advisors fully exited Ascendis Pharma A/S in Q1 2021, selling an estimated $300M.
  • Avoro Capital Advisors's ten largest holdings make up 70% of its $5.79B portfolio in Q1 2021.
  • Avoro Capital Advisors opened 7 new positions and closed 5 in Q1 2021.
  • Avoro Capital Advisors's portfolio value fell 0.28% quarter-over-quarter to $5.79B.

Based on Avoro Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.